1.Almansa, R., Sanchez-Garcia, M., Herrero, A., Calzada, S., Roig, V., Barbado, J., Rico, L., Bobillo, F., Eiros, J.M., Iglesias, V., de Lejarazu, R.O. and Bermejo-Martin, J.F. 2011. Host response cytokine signatures in viral and nonviral acute exacerbations of chronic obstructive pulmonary disease. J. Interferon Cytokine Res., 31(5), 409-413.

2.Bai, Y., Yao, L., Wei, T., Tian, F., Jin, D.Y. and Chen, L. 2020. Presumed asymptomatic carrier transmission of COVID-19. JAMA, 323, 1406-1407.

3.Bhatia, M., Zemans, R.L. and Jeyaseelan, S. 2012. Role of chemokines in the pathogenesis of acute lung injury. Am. J. Respir. Cell Mol. Biol., 46(5), 566-572.

4.Brocker, C., Thompson, D., Matsumoto, A., Nebert, D.W. and Vasiliou, V. 2010. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum. Genomics, 5, 30-55.

5.Cameron, M.J., Bermejo-Martin, J.F., Danesh, A., Muller, M.P. and Kelvin, D.J. 2008. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res., 133(1), 13-19.

6.Chan, J., Yuan, S., Kok, K., To, K., Chu, H. and Yang, J. 2020. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet, 395, 514-523

7.Channappanavar, R. and Perlman, S. 2017. Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol., 39(5), 529-539

8.Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D. and Wang, H. 2020. Clinical and immunologic features in severe and moderate coronavirus disease 2019. J. Clin. Invest., 130, 2620-2629.

9.Chen, L., Liu, H.G., Liu, W., Liu, J., Liu, K., Shang, J., Deng, Y. and Wei, S. 2020. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi, 43, E005

10.Coperchini, F., Chiovato, L., Croce, L., Magri, F. and Rotondi, M. 2020. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev., 53, 25-32

11.Crowe, C.R., Chen, K., Pociask, D.A., Alcorn, J.F., Krivich, C., Enelow, R.I., Ross, T.M., Witztum, J.L. and Kolls, J.K. 2009. Monocyte chemoattractant protein 1 contributes to an adequate immune response in influenza pneumonia. J. Immunol., 183(8), 5301-5310.

12.de Jong, M.D., Simmons, C.P., Thanh, T.T., Hien, V.M., Smith, G.J.D., Chau, T.N.B., Hoang, D.M., Van Vinh Chau,N., Khanh, T.H., Dong, V.C., Qui, P.T., Van Cam, B., Ha, D.Q., Guan, Y., Peiris, J.S.M., Chinh, N.T., Hien, T.T. and Farrar, J. 2006. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat. Med., 12, 1203- 1207.

13.Dessing, M.C., van der Sluijs, K.F., Florquin, S. and van der Poll, T. 2007. Critical role of IL-17RA in immunopathology of influenza infection. Clin. Immunol., 125(3), 328-336.

14.Dinarello, C.A. 2009. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol., 27, 519-550.

15.Fehr, A.R. and Perlman, S. 2015. Coronaviruses: An overview of their replication and pathogenesis. Methods Mol. Biol., 1282, 1-23.

16.Fensterl, V. and Sen, G.C. 2009. Interferons and viral infections. Biofactors, 35, 14-205

17.Gao, Y., Li, T., Han, M., Li, X., Wu, D. and Xu, Y. 2020. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J. Med. Virol., 92, 791-796

18.Gu, J., Han, B. and Wang, J. 2020. COVID-19: Gastrointestinal manifestations and potential fecal-oral transmission. Gastroenterology, 158, 1518-1519

19.Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q. and He, J.X. 2020. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med., 382, 1708-1720

20.Haller, O., Kochs, G. and Weber, F. 2006. The interferon response circuit: Induction and suppression by pathogenic viruses. Virology, 344(1), 119-130.

21.Hayney, M.S., Henriquez, K.M., Barnet, J.H., Ewers, T., Champion, H.M., Flannery, S. and Barrett, B. 2017. Serum IFN- γ-induced protein 10 (IP-10) as a biomarker for severity of acute respiratory infection in healthy adults. J. Clin. Virol., 90: 32-37.

22.Henriquez, K.M., Hayney, M.S., Xie, Y., Zhang, Z. and Barrett, B. 2015. Association of interleukin-8 and neutrophils with nasal symptom severity during acute respiratory infection. J. Med. Virol., 87(2), 330-337

23.Hertzog, P.J., O’Neill, L.A. and Hamilton, J.A. 2003. The interferon in TLR signaling: More than just antiviral. Trends Immunol., 24(10), 534-539

24.Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J. and Hu, Y. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395, 497-506

25.Ishikawa, T. 2012. Clinical preparedness for cytokine storm induced by the highly pathogenic H5N1 influenza virus. J. Pharmacogenomics Pharmacoproteomics, 3, e131.

26.Kalaiyarasu, S., Kumar, M., Kumar, D.S., Bhatia, S., Dash, S.K. and Bhat, S. 2016. Highly pathogenic avian influenza H5N1 virus induces cytokine dysregulation with suppressed maturation of chicken monocyte-derived dendritic cells. Microbiol. Immunol., 60, 687-693.

27.Kash, J.C. 2006. GKash, J.C. 2006. Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature, 443, 578-581.enomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature, 443, 578-581.

28.Katze, M.G., Fornek, J.L., Palermo, R.E., Walters, K.A. and Korth, M.J. 2008. Innate immune modulation by RNA viruses: Emerging insights from functional genomics. Nat. Rev. Immunol., 8, 644-654.

29.Lauer, S.A., Grantz, K.H., Bi, Q., Jones, F.K., Zheng, Q., Meredith, H.R., Azman, A.S., Reich, N.G. and Lessler, J. 2020. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application. Ann. Intern., 172(9), 577-582.

30.Lenzer J. 2020. Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. BMJ, 369, m1335

31.Li, G., Fan, Y., Lai, Y., Han, T., Li, Z., Zhou, P., Pan, P., Wang, W., Hu, D., Liu, X., Zhang, Q. and Wu, J. 2020. Coronavirus infections and immune responses. J. Med. Virol., 92(4), 424-432

32.Liu, Y., Gayle, A.A., Wilder-Smith, A. and Rocklöv, J. 2020. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J. Travel Med., 27(2), taa021

33.McGonagle, D., Sharif, K., O’Regan, A. and Bridgewood, C. 2020. The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun. Rev., 19(6), 102537.

34.Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S. and Manson, J.J. 2020. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet, 395, 1033-1034

35.Michot, J.M., Albiges, L., Chaput, N., Saada, V., Pommeret, F. and Griscelli, F. 2020. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: A case report. Ann. Oncol., 31, 961-964.

36.Neville, L.F., Abdullah, F., McDonnel, P.M., Young, P.R., Feuerstein, G.Z. and Rabinovici, R. 1995. Mob-1 expression in IL-2-induced ARDS: Regulation by TNF-alpha. Am. J. Physiol., 269(6 Pt 1), L884-890

37.Peiris, J.S., Yuen, K.Y., Osterhaus, A.D. and Stöhr, K. 2003. The severe acute respiratory syndrome. N. Engl. J. Med., 349(25), 2431-2441.

38.Perrone, L.A., Szretter, K.J., Katz, J.M., Mizgerd, J.P. and Tumpey, T.M. 2010. Mice lacking both TNF and IL-1 receptors exhibit reduced lung inflammation and delay in onset of death following infection with a highly virulent H5N1 virus. J. Infect. Dis., 202(8), 1161-1170

39.Rotondi, M., Chiovato, L., Romagnani, S., Serio, M. and Romagnani, P. 2007. Role of chemokines in endocrine autoimmune diseases. Endocr. Rev., 28(5), 492-520.

40.Ruan, Q., Yang, K., Wang, W., Jiang, L. and Song, J. 2020. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med., 46, 846-848.

41.Shimizu, M. 2019. Clinical features of cytokine storm syndrome. In: Cron, R., Behrens, E., editors. Cytokine Storm Syndrome. Springer, Cham. pp. 31-42.

42.Szretter, K.J., Gangappa, S., Lu, X., Smith, C., Shieh, W.J., Zaki, S.R., Sambhara, S., Tumpey, T.M. and Katz, J.M. 2007. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J. Virol., 81(6), 2736-2744.

43.Tanaka, T., Narazaki, M. and Kishimoto, T. 2014. IL-6 in inflammation, immunity, and disease. Cold Spring Harb. Perspect. Biol., 6(10), a016295.

44.Thompson, M., Kaminski, J., Kurt-Jones, E. and Fitzgerald, K. 2011. Pattern recognition receptors and the innate immune response to viral infection. Viruses, 3(6), 920-940.

45.Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X. and Zhang, J. 2020. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 323, 1061-1069.

46.Wang, X., Pan, Z. and Cheng, Z. 2020. Association between 2019- nCoV transmission and N95 respirator use. J. Hosp. Infect., 105, 104-105

47.Weber, F., Kochs, G. and Haller, O. 2004. Inverse interference: How viruses fight the interferon system. Viral Immunol., 17(4), 498-515

48.Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., Tai, Y., Bai, C., Gao, T., Song, J., Xia, P., Dong, J., Zhao, J. and Wang, F.S. 2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med., 8(4), 420-422.

49.Yuen, K.Y. and Wong, S.S. 2005. Human infection by avian influenza A H5N1. Hong Kong Med. J., 11, 189-199.

50.Zhang, C., Wu, Z., Li, J.W., Zhao, H. and Wang, G.Q. 2020. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int. J. Antimicrob. Agents, 55(5), 105954

51.Zhao, S., Zhuang, Z., Ran, J., Lin, J., Yang, G. and Yang, L. 2020. The association between domestic train transportation and novel coronavirus (2019-nCoV) outbreak in China from 2019 to 2020: A data-driven correlational report. Travel Med. Infect. Dis., 33, 101568.